Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 2
1989 3
1990 11
1991 4
1992 11
1993 9
1994 11
1995 9
1996 7
1997 10
1998 11
1999 4
2000 10
2001 10
2002 9
2003 14
2004 15
2005 11
2006 14
2007 13
2008 17
2009 29
2010 19
2011 20
2012 37
2013 30
2014 37
2015 51
2016 52
2017 59
2018 56
2019 71
2020 71
2021 80
2022 49
2023 63
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

857 results

Results by year

Filters applied: . Clear all
Page 1
International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Duffield AS, Mullighan CG, Borowitz MJ. Duffield AS, et al. Virchows Arch. 2023 Jan;482(1):11-26. doi: 10.1007/s00428-022-03448-8. Epub 2022 Nov 24. Virchows Arch. 2023. PMID: 36422706 Free PMC article. Review.
The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes both revisions to subtypes previously outlined in the 2016 WHO classification and several newly described entities. …
The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic l …
T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.
Bardelli V, Arniani S, Pierini V, Di Giacomo D, Pierini T, Gorello P, Mecucci C, La Starza R. Bardelli V, et al. Genes (Basel). 2021 Jul 23;12(8):1118. doi: 10.3390/genes12081118. Genes (Basel). 2021. PMID: 34440292 Free PMC article. Review.
T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the bone marrow, mediastinum, central nervous system, and lymphoid organs. ...Among recurrently involved oncogenes, a major role is exerted by T-cell-specifi
T-cell acute lymphoblastic leukemias (T-ALL) are immature lymphoid tumors localizing in the bone marrow, mediastinum, c
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH, Wan CL, Dai HP, Xue SL. Huang YH, et al. Ann Hematol. 2023 Aug;102(8):2001-2013. doi: 10.1007/s00277-023-05286-3. Epub 2023 May 25. Ann Hematol. 2023. PMID: 37227492 Review.
T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. ...These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunot
T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor
T-cell acute lymphoblastic leukemia.
Raetz EA, Teachey DT. Raetz EA, et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):580-588. doi: 10.1182/asheducation-2016.1.580. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913532 Free PMC article. Review.
T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-ALL) counterpart and shows different kinetic patterns of disease response. ...
T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic (B-A
T cell-engaging therapies - BiTEs and beyond.
Goebeler ME, Bargou RC. Goebeler ME, et al. Nat Rev Clin Oncol. 2020 Jul;17(7):418-434. doi: 10.1038/s41571-020-0347-5. Epub 2020 Apr 2. Nat Rev Clin Oncol. 2020. PMID: 32242094 Review.
Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) th …
Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engagi …
Precision medicine in acute lymphoblastic leukemia.
Pui CH. Pui CH. Front Med. 2020 Dec;14(6):689-700. doi: 10.1007/s11684-020-0759-8. Epub 2020 Oct 19. Front Med. 2020. PMID: 33074527 Free PMC article. Review.
BH3 profiling and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cell precursor, immature T-cell, KMT2A-rearranged, Ph-positive and TCF-HLF-positive ALL, that may respond to BCL-2 inhibitor vene …
BH3 profiling and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cell pr
Update on Lymphoblastic Leukemia/Lymphoma.
Luca DC. Luca DC. Clin Lab Med. 2021 Sep;41(3):405-416. doi: 10.1016/j.cll.2021.04.003. Clin Lab Med. 2021. PMID: 34304772 Review.
These neoplastic processes can be of B-cell or T-cell derivation and are composed of immature precursors of either lineage. The classification of B-lymphoblastic neoplasms relies predominantly on genetic and molecular findings, whereas the same is not true fo …
These neoplastic processes can be of B-cell or T-cell derivation and are composed of immature precursors of either lineage. Th …
Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
Kruse A, Abdel-Azim N, Kim HN, Ruan Y, Phan V, Ogana H, Wang W, Lee R, Gang EJ, Khazal S, Kim YM. Kruse A, et al. Int J Mol Sci. 2020 Feb 5;21(3):1054. doi: 10.3390/ijms21031054. Int J Mol Sci. 2020. PMID: 32033444 Free PMC article. Review.
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. Martino M, et al. Int J Mol Sci. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150. Int J Mol Sci. 2021. PMID: 33670075 Free PMC article. Review.
Another issue is the time consuming process of CAR-T engineering. New platforms have shortened the CAR-T cell manufacturing process, and studies are underway to evaluate the effectiveness. Another way to mitigate waiting is the development of allogeneic "off the she …
Another issue is the time consuming process of CAR-T engineering. New platforms have shortened the CAR-T cell manufacturing pr …
857 results